MH
Senior Reporter, GLP-1
Maren Holt
Covers the incretin market, compounded GLP-1 supply and the telehealth companies selling it.
Beats: GLP-1, Compounding · 60 entries on the wire
Lilly's retatrutide beats Ozempic on weight loss in trial
By Maren HoltRetatrutide Vs Ozempic: Next-generation Jab Doubles Weight Loss In Trial
By Maren HoltThe promise and perils of the peptide craze | Hindustan Times
By Maren HoltAssociation of GLP-1 receptor agonist therapy with cardiovascular outcomes in patients with MASLD: A translational study
By Maren HoltPeptides - HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides
By Maren HoltExperimental weight-loss drug retatrutide may help improve sleep apnea
By Maren HoltThis Online GLP-1 Program Costs $69 a Month, and the Price Never Goes Up With Your Dose
By Maren HoltSix Peptides From Our January Guide Just Got a Federal Green Light. Licensed Fighters Still Cannot Touch Them
By Maren HoltCDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
By Maren HoltRetatrutide Tops Ozempic for Weight Loss, A1c in T2D
By Maren HoltHHS Grants Enforcement Discretion for Six Peptides in 503A Compounding Pharmacies
By Maren HoltRetatrutide Beat Ozempic on Blood Sugar and Weight in Diabetes Trial, but More Patients Quit Over Side Effects
By Maren HoltActivities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study
By Maren HoltEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
By Maren HoltOral small-molecule GLP-1 receptor agonist for obesity in people from Japan
By Maren HoltCardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns
By Maren HoltFrom metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders
By Maren HoltGLP-1 Diabetes Drugs Linked to Greater Thyroid Hormone Sensitivity in Large Study
By Maren HoltCertified-PEP Releases 2026 Research Peptide Supplier Comparison, Highlighting Transparency Gaps
By Maren HoltRFK Jr backs compounding of six unapproved peptides in new policy
By Maren HoltHHS Outlines Conditional Enforcement Discretion for 6 Compounded Peptides
By Maren HoltLilly’s Retatrutide Delivers Greater Weight Loss Than Ozempic In Trial
By Maren HoltLilly’s Retatrutide Outperforms Ozempic in Weight Loss and Blood Sugar Control Trial
By Maren HoltSTAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
By Maren HoltThe Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas
By Maren HoltHealth Ministry warns against illegal peptides marketed for weight loss
By Maren HoltOzempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?
By Maren HoltCutaneous vasculitis associated with subcutaneous semaglutide
By Maren HoltEarly Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study
By Maren HoltSemaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
By Maren Holt
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
By Maren HoltSwitching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
By Maren HoltRetatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
By Maren HoltRetatrutide Helped People With Diabetes Lose Twice as Much Weight as Ozempic, New Trial Shows
By Maren HoltEli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial
By Maren HoltHHS Temporarily Allows Compounding Pharmacies to Produce Six Unapproved Peptides
By Maren HoltRetatrutide vs Ozempic: Lilly’s triple-acting drug doubled weight loss in a head-to-head trial
By Maren HoltUS to Allow Compounding of Six Peptides in Temporary Plan
By Maren HoltRetatrutide beats Ozempic on weight loss, blood sugar control, study says
By Maren HoltLilly's retatrutide more than doubled Ozempic weight loss in trial
By Maren HoltLilly’s retatrutide beats Ozempic in head-to-head trial
By Maren HoltNew weight loss drug proves twice as powerful as Ozempic’s highest dosage
By Maren HoltHHS Temporarily Allows Compounding Pharmacies To Make Six Peptides
By Maren HoltHHS Allows Pharmacies to Compound Six Unapproved Peptides
By Maren HoltHHS Allows Six Unapproved Peptides for Pharmacy Compounding
By Maren HoltLilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial
By Maren HoltSTAT+: HHS moves to allow compounding of some unapproved peptides
By Maren HoltLilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
By Maren HoltUS Health Secretary Kennedy opens access to some unapproved peptides
By Maren HoltEli Lilly’s New Drug Shows Double The Weight Loss Of Ozempic In New Study
By Maren HoltIn Head-to-Head Trial, Retatrutide Crushes Ozempic
By Maren HoltSTAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
By Maren HoltSTAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
By Maren HoltHow Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial
By Maren HoltEli Lilly tops Ozempic in Ozempic Vs Retatrutide A1c Study
By Maren HoltSemaglutide shows early bone-building signal in male mice study
By Maren HoltBye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
By Maren HoltSemaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance
By Maren HoltNew weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says - ABC News
By Maren HoltLilly says retatrutide outperformed Ozempic in diabetes study — STAT News
By Maren Holt
